Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant Staphylococcus aureus Endovascular Infections?

被引:13
作者
Rose, Warren [1 ]
Volk, Cecilia [1 ]
Dilworth, Thomas J. [2 ]
Sakoulas, George [3 ]
机构
[1] Univ Wisconsin, Sch Pharm, 777 Highland Ave,Rm 4123, Madison, WI 53705 USA
[2] Advocate Aurora Hlth, Dept Pharm Serv, Milwaukee, WI USA
[3] Univ Calif San Diego, Sch Med, Div Host Microbe Syst & Therapeut, Ctr Immun Infect & Inflammat, La Jolla, CA 92093 USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2022年 / 9卷 / 05期
关键词
bacteremia; efficacy; glycopeptide; MRSA; toxicity; HIGH-DOSE DAPTOMYCIN; DISEASES SOCIETY; MRSA BACTEREMIA; RECENT TRENDS; BETA-LACTAM; ENDOCARDITIS; THERAPY; MORTALITY; EFFICACY; AMERICA;
D O I
10.1093/ofid/ofac137
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vancomycin is the standard antibiotic for serious methicillin-resistant Staphylococcus aureus(MRSA) infections. This perspective highlights how treatment repertoires of many other diseases have changed and advanced since vancomycin's introduction in the 1950s, yet vancomycin, despite its complexity, remains the MRSA treatment standard. Vancomycin was introduced nearly 65 years ago and remains the standard antibiotic for serious methicillin-resistant Staphylococcus aureus (MRSA) infections. Staphylococcus aureus remains highly susceptibility to vancomycin (>97%). Despite this, MRSA treatment failure with vancomycin is high in complicated bacteremia. Additionally, vancomycin can cause nephrotoxicity, leading to new therapeutic drug monitoring guidance. This demonstrates how difficult it is to dose vancomycin in a way that is both efficacious and safe, especially during long courses of therapy. Often underappreciated are the cost, resources, and complexity of vancomycin care at a time when alternative antibiotics are becoming cost comparable. This perspective highlights a bigger picture of how the treatment repertoires of many other diseases have changed and advanced since vancomycin's introduction in the 1950s, yet the vancomycin MRSA treatment standard remains. While vancomycin can still have a role, 65 years may be a practical retirement age for vancomycin in highly complex endovascular infections.
引用
收藏
页数:6
相关论文
共 45 条
  • [1] ANI Pharmaceuticals Inc, 2017, VANC PACK INS
  • [2] Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association
    Baddour, Larry M.
    Wilson, Walter R.
    Bayer, Arnold S.
    Fowler, Vance G., Jr.
    Tleyjeh, Imad M.
    Rybak, Michael J.
    Barsic, Bruno
    Lockhart, Peter B.
    Gewitz, Michael H.
    Levison, Matthew E.
    Bolger, Ann F.
    Steckelberg, James M.
    Baltimore, Robert S.
    Fink, Anne M.
    O'Gara, Patrick
    Taubert, Kathryn A.
    [J]. CIRCULATION, 2015, 132 (15) : 1435 - 1486
  • [3] Balda J, 2021, AM J MED SCI, V362, P562, DOI 10.1016/j.amjms.2021.07.009
  • [4] High-dose daptomycin in documented Staphylococcus aureus infections
    Bassetti, Matteo
    Nicco, Elena
    Ginocchio, Francesca
    Ansaldi, Filippo
    de Florentiis, Daniela
    Viscoli, Claudio
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 36 (05) : 459 - 461
  • [5] Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia
    Beccari, Mario V.
    Seabury, Robert W.
    Mogle, Bryan T.
    Kufel, Wesley D.
    Miller, Christopher D.
    Steele, Jeffrey M.
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (05) : 729 - 733
  • [6] Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations
    Bhavnani, Sujata M.
    Ambrose, Paul G.
    Hammel, Jeffrey P.
    Rubino, Christopher M.
    Drusano, George L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) : 1600 - 1607
  • [7] Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
    Cassini, Alessandro
    Hogberg, Liselotte Diaz
    Plachouras, Diamantis
    Quattrocchi, Annalisa
    Hoxha, Ana
    Simonsen, Gunnar Skov
    Colomb-Cotinat, Melanie
    Kretzschmar, Mirjam E.
    Devleesschauwer, Brecht
    Cecchini, Michele
    Ouakrim, Driss Ait
    Oliveira, Tiago Cravo
    Struelens, Marc J.
    Suetens, Carl
    Monnet, Dominique L.
    Strauss, Reinhild
    Mertens, Karl
    Struyf, Thomas
    Catry, Boudewijn
    Latour, Katrien
    Ivanov, Ivan Nikolaev
    Dobreva, Elina Georgieva
    Tambic Andrasevic, Arjana
    Soprek, Silvija
    Budimir, Ana
    Paphitou, Niki
    Zemlickova, Helena
    Olsen, Stefan Schytte
    Sonksen, Ute Wolff
    Martin, Pille
    Ivanova, Marina
    Lyytikainen, Outi
    Jalava, Jari
    Coignard, Bruno
    Eckmanns, Tim
    Abu Sin, Muna
    Haller, Sebastian
    Daikos, George L.
    Gikas, Achilleas
    Tsiodras, Sotirios
    Kontopidou, Flora
    Toth, Akos
    Hajdu, Agnes
    Guolaugsson, Olafur
    Kristinsson, Karl G.
    Murchan, Stephen
    Burns, Karen
    Dsstat, Patrizio Pezzotti
    Gagliotti, Carlo
    Dumpis, Uga
    [J]. LANCET INFECTIOUS DISEASES, 2019, 19 (01) : 56 - 66
  • [8] The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study
    Chua, Kyra Y. L.
    Vogrin, Sara
    Bury, Susan
    Douglas, Abby
    Holmes, Natasha E.
    Tan, Nixon
    Brusco, Natasha K.
    Hall, Rebecca
    Lambros, Belinda
    Lean, Jacinta
    Stevenson, Wendy
    Devchand, Misha
    Garrett, Kent
    Thursky, Karin
    Grayson, M. Lindsay
    Slavin, Monica A.
    Phillips, Elizabeth J.
    Trubiano, Jason A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (03) : 487 - 496
  • [9] Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
    Claeys, Kimberly C.
    Zasowski, Evan J.
    Casapao, Anthony M.
    Lagnf, Abdalhamid M.
    Nagel, Jerod L.
    Nguyen, Cynthia T.
    Hallesy, Jessica A.
    Compton, Mathew T.
    Kaye, Keith S.
    Levine, Donald P.
    Davis, Susan L.
    Rybak, Michael J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (10) : 5841 - 5848
  • [10] Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review
    Cosimi, Reese A.
    Beik, Nahal
    Kubiak, David W.
    Johnson, Jennifer A.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (02):